In vitro potency determination of botulinum neurotoxin B based on its receptor-binding and proteolytic characteristics

Toxicology in Vitro

Volumn 34, Issue , 2016, Pages 97-104

  Wild, Emina ^a   Bonifas, Ursula ^a   Klimek, Jolanta ^a   Trösemeier, Jan Hendrik ^a,b   Krämer, Beate ^a   Kegel, Birgit ^a   Behrensdorf Nicol, Heike A ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

3R; Activity determination; Binding and cleavage ability; Botulinum neurotoxin serotype B; In vitro assay; Synaptobrevin

Indexed keywords

BOTULINUM TOXIN B; EPITOPE; NEOEPITOPE; SYNAPTOBREVIN; UNCLASSIFIED DRUG; BOTULINUM TOXIN A; GANGLIOSIDE; PROTEIN BINDING; SYNAPTOBREVIN 2; SYNAPTOTAGMIN II; SYT2 PROTEIN, MOUSE; TRISIALOGANGLIOSIDE GT1; VAMP2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; LD50; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN FUNCTION; RECEPTOR BINDING; BIOASSAY; METABOLISM; PROTEIN DEGRADATION;

BIOLOGICAL ASSAY; BOTULINUM TOXINS, TYPE A; GANGLIOSIDES; PROTEIN BINDING; PROTEOLYSIS; SYNAPTOTAGMIN II; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 84962695704     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.03.011     Document Type: Article

References (43)

1. Abrams S.B., Hallett M. Clinical utility of different botulinum neurotoxin preparations. Toxicon 2013, 67:81-86. 10.1016/j.toxicon.2012.11.024.
2. Adam-Castrillo D., White N.A., Donaldson L.L., Furr M.O. Effects of injection of botulinum toxin type B into the external anal sphincter on anal pressure of horses. Am. J. Vet. Res. 2004, 65(1):26-30.
3. Adler M., Shafer H.F., Manley H.A., Hackley B.E., Nicholson J.D., Keller J.E., Goodnough M.C. A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity. J. Protein Chem. 2003, 22(5):441-448.
4. Adler S., Bicker G., Bigalke H., Bishop C., Blümel J., Dressler D., Fitzgerald J., Gessler F., Heuschen H., Kegel B., Luch A., Milne C., Pickett A., Ratsch H., Ruhdel I., Sesardic D., Stephens M., Stiens G., Thornton P.D., Thürmer R., Vey M., Spielmann H., Grune B., Liebsch M. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern. Lab. Anim. 2010, 38(4):315-330.
5. Behrensdorf-Nicol H.A., Bonifas U., Kegel B., Silberbach K., Krämer B., Weisser K. In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step. Toxicol. In Vitro 2010, 24(3):988-994. 10.1016/j.tiv.2009.12.018.
6. Behrensdorf-Nicol H.A., Bonifas U., Hanschmann K.-M., Krämer B., Weißer K. Binding and cleavage (BINACLE) assay for the functional in vitro detection of tetanus toxin: applicability as alternative method for the safety testing of tetanus toxoids during vaccine production. Vaccine 2013, 31(52):6247-6253. 10.1016/j.vaccine.2013.10.028.
7. Berntsson R.P.-A., Peng L., Dong M., Stenmark P. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 2013, 4:2058. 10.1038/ncomms3058.
8. Bitz S. The botulinum neurotoxin LD50 test - problems and solutions. ALTEX 2010, 27(2):114-116.
9. Boyer A.E., Moura H., Woolfitt A.R., Kalb S.R., McWilliams L.G., Pavlopoulos A., Schmidt J.G., Ashley D.L., Barr J.R. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal. Chem. 2005, 77(13):3916-3924. 10.1021/ac050485f.
10. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., Jankovic J., O'Brien C., Murray J.J., Wallace J.D., Willmer-Hulme A., Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999, 53(7):1431-1438.
11. Caccin P., Rossetto O., Rigoni M., Johnson E., Schiavo G., Montecucco C. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett. 2003, 542(1-3):132-136.
12. Council of Europe Botulinum toxin type A for injection: European Pharmacopoeia 8.6. Monograph 2113 2016.
13. Council of Europe Botulinum toxin type B for injection: European Pharmacopoeia 8.6. Monograph 2581 2016.
14. Dean R.B., Dixon W.J. Simplified statistics for small numbers of observations. Anal. Chem. 1951, 23(4):636-638.
15. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., Chapman E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 2003, 162(7):1293-1303. 10.1083/jcb.200305098.
16. Donovan J.J., Middlebrook J.L. Ion-conducting channels produced by botulinum toxin in planar lipid membranes. Biochemistry 1986, 25(10):2872-2876.
17. Dunning F.M., Ruge D.R., Piazza T.M., Stanker L.H., Zeytin F.N., Tucker W.C. Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to femtomolar sensitivity. Appl. Environ. Microbiol. 2012, 78(21):7687-7697. 10.1128/AEM.01664-12.
18. Fernández-Salas E., Wang J., Molina Y., Nelson J.B., Jacky Birgitte P.S., Aoki K.R. Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One 2012, 7(11). 10.1371/journal.pone.0049516.
19. Finkelstein A. Channels formed in phospholipid bilayer membranes by diphtheria, tetanus, botulinum and anthrax toxin. J. Physiol. 1990, 84(2):188-190.
20. Fischer A., Montal M. Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon 2013, 75:101-107. 10.1016/j.toxicon.2013.01.007.
21. German Federal Institute for Risk Assessment Animaltestinfo (Accessed 14 January 2016). http://www.animaltestinfo.de.
22. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 1982, 46(1):86-94.
23. Gu S., Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol. 2013, 364:21-44. 10.1007/978-3-642-33570-9_2.
24. Kegel B., Behrensdorf-Nicol H.A., Bonifas U., Silberbach K., Klimek J., Krämer B., Weisser K. An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. Toxicol. In Vitro 2007, 21(8):1641-1649. 10.1016/j.tiv.2007.06.015.
25. Kumemoto R., Yusa K., Shibayama T., Hatori K. Trimethylamine N-oxide suppresses the activity of the actomyosin motor. Biochim. Biophys. Acta 2012, 1820(10):1597-1604. 10.1016/j.bbagen.2012.06.006.
26. Ma J., Pazos I.M., Gai F. Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO). Proc. Natl. Acad. Sci. U. S. A. 2014, 111(23):8476-8481. 10.1073/pnas.1403224111.
27. Merz Pharma Alternative test method for botulinum neurotoxin now approved in Europe (Accessed 14 January 2016). https://www.merz.com//app/uploads/2015/12/20151211PM-BfArM-Zulassung-alternative-Testmethode_EN_v.pdf.
28. Montecucco C., Schiavo G. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem. Sci. 1993, 18(9):324-327.
29. Nuss J.E., Wanner L.M., Tressler L.E., Bavari S. The osmolyte trimethylamine N-oxide (TMAO) increases the proteolytic activity of botulinum neurotoxin light chains A, B, and E: implications for enhancing analytical assay sensitivity. J. Biomol. Screen. 2010, 15(8):928-936. 10.1177/1087057110374996.
30. Pathe-Neuschäfer-Rube A., Neuschäfer-Rube F., Genz L., Püchel G.P. Botulinum neurotoxin dose-dependently inhibits release of neurosecretory vesicle-vargeted luciferase from neuronal cells. ALTEX 2015, 32(4):297-306. 10.14573/altex.1503061.
31. Pellett S., Tepp W.H., Toth S.I., Johnson E.A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 2010, 61(3):304-310. 10.1016/j.vascn.2010.01.003.
32. Pirazzini M., Bordin F., Rossetto O., Shone C.C., Binz T., Montecucco C. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 2013, 587(2):150-155. 10.1016/j.febslet.2012.11.007.
33. Pirazzini M., Azarnia Tehran D., Zanetti G., Megighian A., Scorzeto M., Fillo S., Shone C.C., Binz T., Rossetto O., Lista F., Montecucco C. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 2014, 8(6):1870-1878. 10.1016/j.celrep.2014.08.017.
34. R Core Team R: A Language and Environment for Statistical Computing 2013, R Foundation for Statistical Computing, (URL http://www.R-project.org/).
35. Rasetti-Escargueil C., Jones R.G.A., Liu Y., Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009, 53(5):503-511. 10.1016/j.toxicon.2009.01.019.
36. Ritz C., Streibig J.C. Bioassay analysis using R. J. Stat. Softw. 2005, 12.
37. Rossetto O., Pirazzini M., Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nature reviews. Microbiology 2014, 12(8):535-549. 10.1038/nrmicro3295.
38. Sakamoto Y., Ishiguro M., Kitagawa G. Akaike Information Criterion Statistics: Information Criterion Statistics 1986.
39. 50 assay for botulinum toxin potency testing: strategies and progress towards refinement, reduction and replacement. AATEX 2007, 14(Special Issue):581-585.
40. Sugii S., Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect. Immun. 1975, 12(6):1262-1270.
41. Wagman J., Bateman J.B. Botulinum type A toxin: properties of a toxic dissociation product. Arch. Biochem. Biophys. 1953, 45(2):375-383.
42. Whitemarsh R.C.M., Strathman M.J., Chase L.G., Stankewicz C., Tepp W.H., Johnson E.A., Pellett S. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol. Sci. 2012, 126(2):426-435. 10.1093/toxsci/kfr354.
43. Wijnberg I.D., Schrama S.E.A., Elgersma A.E., Maree J.T.M., de Cocq P., Back W. Quantification of surface EMG signals to monitor the effect of a Botox treatment in six healthy ponies and two horses with stringhalt: preliminary study. Equine Vet. J. 2009, 41(3):313-318.